FDA Classifies New Tinnitus Stimulation Device
Published Date: 6/10/2026
Rule
Summary
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Device reclassified to Class II, speeding access
The FDA classified the combined acoustic and electrical external stimulation device for tinnitus as Class II (special controls), effective June 10, 2026, and applicable retroactively to March 6, 2023. FDA says this Class II classification reduces regulatory burdens compared with automatic Class III assignment and will enhance patients' access to this device.
Creates a predicate pathway for future devices
FDA's De Novo classification means this device type can serve as a predicate for future substantially equivalent devices, allowing other sponsors to use the less burdensome 510(k) premarket notification process instead of De Novo or premarket approval. The order explains that after classification into class I or II via De Novo, future device sponsors can rely on this device as a predicate.
Mandatory safety tests and prescriber-only labeling
The Class II order imposes special controls requiring clinical performance testing, non-clinical verification of electrical and acoustic parameters, electromagnetic compatibility and battery safety testing, software verification/validation and hazard analysis, biocompatibility of patient-contacting components, and human factors testing. Labeling must state that the device is intended to be prescribed by a healthcare professional with expertise in evaluation and management of tinnitus and must include device specifications (e.g., electrical output waveform, stimulation peak voltage and current, pulse duration, frequency, maximum current density, maximum phase charge, and power source).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18529, Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
The FDA wants your thoughts on how they collect info to track medical devices. This affects companies that make or handle these devices and aims to keep things safe and clear. You’ve got until November 10, 2026, to share your comments—no cost, just your voice!
2026-18612, Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18551, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
Previous / Next Documents
Previous: 2026-11585, Penalty Inflation Adjustments for Civil Monetary Penalties
Starting June 10, 2026, the Social Security Administration is updating its civil penalty amounts to keep up with inflation. This means fines for breaking certain rules will be a bit higher to match today’s prices. If you deal with SSA rules, watch out—penalties are now adjusted every year to stay fair and current!
Next: 2026-11592, Publication of Cyber-Related Sanctions Regulations Web General License 2
The Treasury’s Office of Foreign Assets Control (OFAC) officially published General License 2, which lets certain water treatment and distribution transactions with Anco Water Supply Co. Ltd. happen, even though sanctions usually block them. This change helps companies involved in drinking water services keep things flowing smoothly without breaking the rules. The license took effect on April 23, 2026, so affected businesses should act now to stay compliant and avoid penalties.